ASX:OSL

Taylor Collison Starts OncoSil Medical at Speculative Buy with AU$1.46 Price Target

OncoSil Medical Says Encouraging Pancreatic Cancer Therapy Data to Be Presented at Chicago Conference; Shares Gain 13%

OncoSil Medical (ASX:OSL) said data highlighting the "excellent safety" of its OncoSil device for the treatment of pancreatic cancer will be presented at an American Society of Clinical Oncology conference in Chicago on May 30, according to a Friday filing with the Australian bourse.The data to be presented shows "a high percentage of surgical resection rates" achieved in locally advanced pancreatic cancer patients who were deemed unresectable at diagnosis, per the filing.The treatment with the OncoSil device showed a favorable safety profile and a median progression-free survival of 8.5 months, the company said.Shares of OncoSil Medical advanced nearly 13% in recent Friday trade.